Authorities Deem Novartis’ FLUAD Safe

The Italian AIFA and National institute of Health (ISS) have declared Novartis’ FLUAD as safe Towards the end of November Italian officials prohibited the use of two batches of Novartis’ flu vaccine FLUAD after 13 deaths were reported to have taken place shortly after vaccination (8 within 24 hours). There were concerns from the AIFA that there may have been …

Novartis: Safety and efficacy of Fluad vaccinations in Italy

November 28, 2014 Regarding the precautionary suspension of two batches of Fluad in Italy, Novartis underlines that no causal relationship to the vaccine has been established to date. Fluad is approved for vaccination of elderly patients (65+) and often prescribed to patients who suffer from pre-existing underlying medical conditions and have a weaker immune system. Serious medical events and deaths …

GSK Get The Go-ahead for Acquisition of Novartis’ Vaccines Business

Regulatory update on transaction with Novartis November 26, 2014 GlaxoSmithKline plc is today providing this update to its announcement of 22 April 2014 relating to the major three-part transaction with Novartis AG (the Original Announcement). The US Federal Trade Commission (FTC) has voted to approve GSK’s proposed acquisition of Novartis’s vaccines business (excluding influenza vaccines) and the proposed creation of …

GSK Statement on First Phase 1 Trial Results of a Candidate Ebola Vaccine

November 24, 2014 First results from a small phase 1 trial published today in the New England Journal of Medicine show that a GSK/NIH Ebola candidate vaccine was well-tolerated and produced an immunological response in each of the 20 healthy adult volunteers in the USA who received it. The candidate vaccine used in the trial conducted by the National Institutes …

Novartis and Malaria No More help fulfill malaria treatment goal in Zambia by raising funds for three million treatments through Power of One

  Power of One campaign, supported by exclusive treatment sponsor Novartis, raises funds for three million treatments for children with malaria Novartis associates rallied behind Power of One to fund close to 500 000 antimalarial treatments for Zambia Company reaches delivery landmark with 700 million antimalarial treatments supplied without profit in 60 malaria-endemic countries since 2001 November 12, 2014 Novartis announced …

What Lies Ahead for The Vaccine Industry?

  We’ve got to ‘fight our corner’ was the message from Novartis’ David McIntosh as he opened up the 2014 World Vaccine Congress Europe You opened the conference this morning with the claim that ‘we need to fight our corner’ in the vaccine industry. Is the vaccine industry in trouble?   The pharmaceutical industry is broadly divided into pharma products …

The Most Influential People in Vaccines

Vaccine Nation presents the 50 most influential people in vaccines Download the Most Influential People in Vaccines to find out: Has Bill Gates lost his top spot? Who are the 25 new entries? Which disease field has produced the most influential experts Over the last two months we asked you to vote for who you believe are the three most influential …

Novartis vaccine Bexsero sees high uptake in first large-scale public vaccination program to help protect against devastating meningitis B

July 29th, 2014 Program in Québec’s Saguenay-Lac-Saint-Jean region is the first public campaign globally to offer Bexsero to all from 2 months to 20 years of age More than 45,000 infants, young children and adolescents included in the program have already received at least one dose of Bexsero Swift implementation, within 6 months of approval, marks a milestone in helping …